Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is reporting third quarter earnings results on Friday 30th October 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 0.98 per share.
For the full year, analysts predict revenues of $ 170.22 million, while looking forward to income of $ 3.91 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 170.00 million ~ $ 170.00 million, where as bottomline are predicted in a range of $ 3.95 ~ $ 3.95 per share
Click Here For More Historical Outlooks Of Ligand Pharmaceuticals Incorporated
Previous Quarter Performance
Ligand Pharmaceuticals Incorporated communicated income for the second quarter of $ 1.00 per share, from the revenue of $ 41.42 million. The quarterly earnings 47.06 percent while revenues increased 65.75 percent compared with the same quarter last year.
According to street consensus, LGND was expected to report 2Q20 income of $ 0.76 per share from revenue of $ 31.39 million. The bottom line results beat street analysts by $ 0.24 or 31.58 percent, at the same time, top line results outshined analysts by $ 10.03 million or 31.95 percent.
Stock Performance
Shares of Ligand Pharmaceuticals Incorporated traded low $ -1.35 or -1.60 percent on Thursday, reaching $ 83.07 with volume of 456.70 thousand shares. Ligand Pharmaceuticals Incorporated has traded high as $ 85.92 and has cracked $ 80.46 on the downward trend
According to the previous trading day, closing price of $ 83.07, representing a 47.48 % increase from the 52 week low of $ 57.24 and a 33.94 % decrease over the 52 week high of $ 127.80.
The company has a market capital of $ 1.34 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Ligand Pharmaceuticals Incorporated will be hosting a conference call at 8:30 AM eastern time on 30th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.ligand.com
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The companys partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others.
